|
Connective Tissue Oncology Society |
|
 |
| 2001 CTOS Annual Meeting Posters— Medical Oncology A RETROSPECTIVE
REVIEW OF MAYO CLINIC'S PHASE II CLINICAL TRIALS OF ADVANCED SARCOMAS
TO EXAMINE SURVIVAL DIFFERENCES BETWEEN LEIOMYOSARCOMAS OF THE GI
ORIGIN (GIST) VERSUS NON-GI ORIGIN. OBJECTIVE: Recent reports suggest that patients with metastatic GIST have inferior survival compared to patients with non-GI leiomyosarcoma. Previously GISTs were classified as leiomyosarcomas of the GI tract and clinical experience has shown that these tumors of the gut behaved differently to treatment regimens than similar tumors of non-GI origin. GISTs are now classified as mesenchymal tumors of Cajal cells which express c-kit and are responsive to the small molecule STI-571. We wanted to verify if survival differences were evident in our leiomyosarcoma patients (GIST vs non-GIST). METHODS: We reviewed from our previous 12 phase II studies for advanced sarcoma and identified 93 of 430 patients diagnosed with leiomyosarcoma. These patients were entered into the phase II studies from 1971-1992 and largely when surgical options were exhausted. Treatments included adriamycin; methyl-CCNU, actinomycin D, cytoxan, vincristine; adriamycin, imidazole carboxamide, vincristine; pyrazofurin; cytoxan, adriamycin, cisplatin; maytansine; mitomycin, adriamycin, cisplatin; menogaril; interferon gamma; ifosfamide, etoposide; ifosfamide, mitomycin, adriamycin, cisplatin; and taxotere. Because of limited samples and age of the tissue, staining for c-kit (CD 117) was not performed. RESULTS: Thirty-six (39%) cases were classified as GIST (vs 57 non-GIST). Ninety-one patients have died. Kaplan-Meier estimates are as follow:
CONCLUSION: In our retrospective review of patients on 12 advanced sarcoma Phase II clinical trials, we observed no statistically significant difference in survival between patients with advanced leiomyosarcomas of the GI versus those of non-GI origin.
|
